| 摘要 |
<p>A novel formulation which contains about 2-60 % by calories of a C20 or longer φ3 fatty acid moiety and about 2-60 % by calories of an arachidonic acid moiety has been developed. This formulation is particularly useful for restoring arachidonic acid levels, increasing immunity or minimizing risk of infection in critically ill patients, and treating functional essential fatty acid deficiency in patients suffering from end stage liver disease. A structured lipid which has a C20 or longer φ3 fatty acid moiety and an arachidonic acid moiety has also been developed.</p> |
